Highlights Inhibrx, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
16.24 ^USD	-3.85%		-50.44%	-57.26%

Jun. 04	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
May. 31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Sanofi Closes Purchase of US Biotech Company Inhibrx	May. 30	MT
Sanofi: acquisition of Inhibrx finalized	May. 30	CF
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	May. 29	CI
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	May. 29	CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	May. 24	MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Inhibrx Shares Fall After Q4 Net Loss Widens	Feb. 28	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	Feb. 28	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	Feb. 01	AN
Health Care Flat After J&J Earnings -- Health Care Roundup	Jan. 23	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	Jan. 23	AN
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	Jan. 23	MT
CAC40: falls back below 7,400, Wall-Street reopens unchanged	Jan. 23	CF
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak	Jan. 23	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	Jan. 23	DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion	Jan. 23	MT
CAC40: little movement, caution prevails	Jan. 23	CF
Sanofi: agreement to acquire Inhibrx	Jan. 23	CF

No results for this search